Jonathan Paris - Rapid Micro Gen VP
| RPID Stock | USD 2.59 0.14 5.71% |
Insider
Jonathan Paris is Gen VP of Rapid Micro Biosystems
| Age | 48 |
| Phone | 978 349 3200 |
| Web | https://www.rapidmicrobio.com |
Jonathan Paris Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Paris against Rapid Micro stock is an integral part of due diligence when investing in Rapid Micro. Jonathan Paris insider activity provides valuable insight into whether Rapid Micro is net buyers or sellers over its current business cycle. Note, Rapid Micro insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rapid Micro'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Paris over a year ago Acquisition by Jonathan Paris of 86700 shares of Rapid Micro subject to Rule 16b-3 | ||
Jonathan Paris over a year ago Payment of 5054 shares by Jonathan Paris of Rapid Micro subject to Rule 16b-3 |
Rapid Micro Management Efficiency
The company has return on total asset (ROA) of (0.2583) % which means that it has lost $0.2583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.485) %, meaning that it created substantial loss on money invested by shareholders. Rapid Micro's management efficiency ratios could be used to measure how well Rapid Micro manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Christopher Holland | Electromed | 55 | |
| Mark Quick | Orthofix Medical | N/A | |
| Michael Hutchinson | LivaNova PLC | 54 | |
| Bradford Amman | Vivos Therapeutics | 63 | |
| Lisa Paul | Pulmonx Corp | 61 | |
| Mark CPA | Treace Medical Concepts | 54 | |
| Matt Haller | Rxsight | N/A | |
| David Kizer | Owlet Inc | N/A | |
| Leigh Salvo | IRIDEX | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Kathryn Scolnick | Owlet Inc | 55 | |
| Jennifer Ernst | Tivic Health Systems | 57 | |
| Kurt Workman | Owlet Inc | 36 | |
| John McKune | Pulmonx Corp | 49 | |
| BA Chemistry | Orthofix Medical | 63 | |
| Blake Gurfein | Tivic Health Systems | 41 | |
| Fuad Ahmad | IRIDEX | 55 | |
| Jason Cook | Bluejay Diagnostics | 43 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| RaeAnn Byrnes | Vivos Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.26 |
Rapid Micro Biosystems Leadership Team
Elected by the shareholders, the Rapid Micro's board of directors comprises two types of representatives: Rapid Micro inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rapid. The board's role is to monitor Rapid Micro's management team and ensure that shareholders' interests are well served. Rapid Micro's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rapid Micro's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Spignesi, President CEO | ||
| John Wilson, Chief Officer | ||
| Michael CFA, Vice Communications | ||
| Kristine Williams, Senior Management | ||
| Jonathan Paris, Gen VP | ||
| Sean CPA, Chief Officer | ||
| Victoria Vezina, Chief Officer | ||
| Michael Wysocki, Senior Marketing | ||
| James Xu, VP Secretary | ||
| Sean Wirtjes, Chief Officer |
Rapid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rapid Micro a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.67) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 61.37 M | ||||
| Shares Outstanding | 38.74 M | ||||
| Shares Owned By Insiders | 9.26 % | ||||
| Shares Owned By Institutions | 54.41 % | ||||
| Number Of Shares Shorted | 134.45 K | ||||
| Price To Book | 1.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Rapid Micro Biosystems is a strong investment it is important to analyze Rapid Micro's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rapid Micro's future performance. For an informed investment choice regarding Rapid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rapid Micro Biosystems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Wireless Telecommunication Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rapid Micro. If investors know Rapid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rapid Micro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rapid Micro Biosystems is measured differently than its book value, which is the value of Rapid that is recorded on the company's balance sheet. Investors also form their own opinion of Rapid Micro's value that differs from its market value or its book value, called intrinsic value, which is Rapid Micro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rapid Micro's market value can be influenced by many factors that don't directly affect Rapid Micro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rapid Micro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rapid Micro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rapid Micro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.